MIA RYCKMAN: Open Payments
NPI 1417591348 · CHANDLER, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,564 in 78 payments from 18 companies in 2025. Trend: 2023 $1,193 · 2024 $1,482 · 2025 $1,564
Food & beverage: $1,564
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $414 |
| Janssen Biotech, Inc. | 10 | $227 |
| Ardelyx, Inc. | 6 | $161 |
| PFIZER INC. | 5 | $89 |
| Ipsen Biopharmaceuticals, Inc | 4 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| Madrigal Pharmaceuticals | 3 | $79 |
| GENZYME CORPORATION | 2 | $65 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $65 |
| Lilly USA, LLC | 3 | $64 |
Products named: TREMFYA, RINVOQ, IBSRELA, SKYRIZI, IQIRVO, ENTYVIO, DUPIXENT, REZDIFFRA.
Industry payments across AZ — which companies pay providers there.
